登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，3月10日，Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-11

  • Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay

    James P Broughton, Xianding Deng, Guixia Yu, Clare L Fasching, Jasmeet Singh, Jessica Streithorst, Andrea Granados, Alicia Sotomayor-Gonzalez, Kelsey Zorn, Allan Gopez, Elaine Hsu, Wei Gu, Steven Miller, Chao-Yang Pan, Hugo Guevara, Debra Wadford, Janice Chen, Charles Y Chiu

    doi: https://doi.org/10.1101/2020.03.06.20032334

    Abstract

    An outbreak of novel betacoronavirus, SARS-CoV-2 (formerly named 2019-nCoV), began in Wuhan, China in December 2019 and the COVID-19 disease associated with infection has since spread rapidly to multiple countries. Here we report the development of SARS-CoV-2 DETECTR, a rapid (~30 min), low-cost, and accurate CRISPR-Cas12 based lateral flow assay for detection of SARS-CoV-2. We validated this method using contrived reference samples and clinical samples from infected US patients and demonstrated comparable performance to the US CDC SARS-CoV-2 real-time RT-PCR assay.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.03.06.20032334v1
109浏览量
原文链接
相关报告

  • 《Nature，4月16日，CRISPR–Cas12-based detection of SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-17
    • CRISPR–Cas12-based detection of SARS-CoV-2 James P. Broughton, Xianding Deng, Guixia Yu, Clare L. Fasching, Venice Servellita, Jasmeet Singh, Xin Miao, Jessica A. Streithorst, Andrea Granados, Alicia Sotomayor-Gonzalez, Kelsey Zorn, Allan Gopez, Elaine Hsu, Wei Gu, Steve Miller, Chao-Yang Pan, Hugo Guevara, Debra A. Wadford, Janice S. Chen & Charles Y. Chiu Nature Biotechnology (2020) Abstract An outbreak of betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 began in Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 infection, rapidly spread to produce a global pandemic. We report development of a rapid (<40 min), easy-to-implement and accurate CRISPR–Cas12-based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated our method using contrived reference samples and clinical samples from patients in the United States, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections.
    223浏览量
    原文链接

  • 《MedRxiv，2月23日，Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-02-24
    • Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus Tieying Hou, Weiqi Zeng, Minling Yang, Wenjing Chen, Lili Ren, Jingwen Ai, Ji Wu, Yalong Liao, Xuejing Gou, Yongjun Li, Xiaorui Wang, Hang Su, Jianwei Wang, Bing Gu, Teng Xu doi: https://doi.org/10.1101/2020.02.22.20025460 Abstract Background: The recent outbreak of infections by the 2019 novel coronavirus (2019-nCoV), the third zoonotic CoV has raised great public health concern. The demand for rapid and accurate diagnosis of this novel pathogen brought significant clinical and technological challenges. Currently, metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR (RT-PCR) are the most widely used molecular diagnostics. Methods: 2019-nCoV infections were confirmed in 52 specimens by mNGS. Genomic information was analyzed and used for the design and development of an isothermal, CRISPR-based diagnostic for this novel virus. The diagnostic performance of CRISPR-nCoV was assessed and compared across three technology platforms (mNGS, RT-PCR and CRISPR). Results: 2019-nCoVs sequenced in our study were conserved with the Wuhan strain, and shared certain genetic similarity with SARS-CoV. A high degree of variation in the level of viral RNA was observed in clinical specimens. CRISPR-nCoV demonstrated a near single-copy sensitivity and great clinical sensitivity with a shorter turn-around time than RT-PCR. Conclusion: CRISPR-nCoV presents as a promising diagnostic option for the emerging pathogen. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    73浏览量
    原文链接